Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-10-29

Clinical Trial Update: Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating the combination of nivolumab and axitinib in patients with advanced renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INLYTA (AXITINIB)
  • OPDIVO (nivolumab)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING